Blood microRNAs identified as potential biomarkers for mild cognitive impairment and Alzheimer's progression.

Recent studies highlight the potential of blood microRNAs as biomarkers for diagnosing mild cognitive impairment (MCI) and predicting its progression to Alzheimer's dementia. Conducted by researchers from Boston University and others, the findings suggest that these microRNAs could facilitate early, non-invasive, and cost-effective testing. This research may enhance understanding of Alzheimer's mechanisms, paving the way for new therapeutic targets and early intervention strategies.